Download PDF
Semin Reprod Med 2010; 28(5): 360-369
DOI: 10.1055/s-0030-1262895
© Thieme Medical Publishers

Early Menopause: Primary Ovarian Insufficiency and Surgical Menopause

Pinar H. Kodaman1
  • 1Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut
Further Information

Publication History

Publication Date:
15 September 2010 (online)

    Permissions and Reprints

ABSTRACT

Early menopause, whether a consequence of primary ovarian insufficiency or resulting from surgical removal of gonads in a premenopausal woman, offers unique health-related challenges. Premature deprivation of sex steroids sets into motion a cascade of events that preferentially target urogenital, skeletal, cardiovascular, and neurocognitive systems, and culminate in global health deterioration in a chronologically younger population of women compared with those undergoing age-appropriate, natural menopause. Overtly, menopausal symptoms may be shared between those experiencing early menopause versus those undergoing a natural attrition of their reproductive physiology. Extrapolation of concerns emanating from recent randomized trials of menopausal hormone therapy may not be applicable to young women experiencing early menopause, however, and estrogen replacement remains a mainstay in the clinical management of this population.

KEYWORDS

primary ovarian insufficiency - surgical menopause - hormone therapy

REFERENCES

  • 1 van Noord P A, Dubas J S, Dorland M, Boersma H, te Velde E. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors.  Fertil Steril. 1997;  68(1) 95-102
    CrossrefPubMedGoogle Scholar
  • 2 Kalantaridou S N, Nelson L M. Premature ovarian failure is not premature menopause.  Ann N Y Acad Sci. 2000;  900 393-402
    CrossrefPubMedGoogle Scholar
  • 3 Nelson L, Anasti J N, Kimzey L M. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure.  J Clin Endocrinol Metab. 1994;  79 1470-1475
    CrossrefPubMedGoogle Scholar
  • 4 Alper M M, Jolly E E, Garner P R. Pregnancies after premature ovarian failure.  Obstet Gynecol. 1986;  67(3, Suppl) 59S-62S
    CrossrefPubMedGoogle Scholar
  • 5 Rebar R W, Connolly H V. Clinical features of young women with hypergonadotropic amenorrhea.  Fertil Steril. 1990;  53(5) 804-810
    PubMedGoogle Scholar
  • 6 Rebar R W. Premature ovarian failure.  Obstet Gynecol. 2009;  113(6) 1355-1363
    CrossrefPubMedGoogle Scholar
  • 7 Albright F, Smith P H, Fraser R. A syndrome characterized by primary ovarian insufficiency.  Am J Med Sci. 1942;  204 625-648
    CrossrefPubMedGoogle Scholar
  • 8 Welt C K. Primary ovarian insufficiency: a more accurate term for premature ovarian failure.  Clin Endocrinol (Oxf). 2008;  68(4) 499-509
    CrossrefPubMedGoogle Scholar
  • 9 Nelson L M. Clinical practice. Primary ovarian insufficiency.  N Engl J Med. 2009;  360(6) 606-614
    CrossrefPubMedGoogle Scholar
  • 10 Coulam C B, Adamson S C, Annegers J F. Incidence of premature ovarian failure.  Obstet Gynecol. 1986;  67(4) 604-606
    PubMedGoogle Scholar
  • 11 Sklar C A, Mertens A C, Mitby P et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study.  J Natl Cancer Inst. 2006;  98(13) 890-896
    CrossrefPubMedGoogle Scholar
  • 12 Panay N, Fenton A. Premature ovarian failure: a growing concern.  Climacteric. 2008;  11(1) 1-3
    PubMedGoogle Scholar
  • 13 Singh R P, Carr D H. The anatomy and histology of XO human embryos and fetuses.  Anat Rec. 1966;  155(3) 369-383
    CrossrefPubMedGoogle Scholar
  • 14 Cunniff C, Jones K L, Benirschke K. Ovarian dysgenesis in individuals with chromosomal abnormalities.  Hum Genet. 1991;  86(6) 552-556
    PubMedGoogle Scholar
  • 15 Modi D N, Sane S, Bhartiya D. Accelerated germ cell apoptosis in sex chromosome aneuploid fetal human gonads.  Mol Hum Reprod. 2003;  9(4) 219-225
    CrossrefPubMedGoogle Scholar
  • 16 Bannatyne P, Russell P, Shearman R P. Autoimmune oophoritis: a clinicopathologic assessment of 12 cases.  Int J Gynecol Pathol. 1990;  9(3) 191-207
    CrossrefPubMedGoogle Scholar
  • 17 Sedmak D D, Hart W R, Tubbs R R. Autoimmune oophoritis: a histopathologic study of involved ovaries with immunologic characterization of the mononuclear cell infiltrate.  Int J Gynecol Pathol. 1987;  6(1) 73-81
    CrossrefPubMedGoogle Scholar
  • 18 Morrison J C, Givens J R, Wiser W L, Fish S A. Mumps oophoritis: a cause of premature menopause.  Fertil Steril. 1975;  26(7) 655-659
    PubMedGoogle Scholar
  • 19 Panay N, Kalu E. Management of premature ovarian failure.  Best Pract Res Clin Obstet Gynaecol. 2009;  23(1) 129-140
    CrossrefPubMedGoogle Scholar
  • 20 Farhi J, Homburg R, Ferber A, Orvieto R, Ben Rafael Z. Non-response to ovarian stimulation in normogonadotrophic, normogonadal women: a clinical sign of impending onset of ovarian failure pre-empting the rise in basal follicle stimulating hormone levels.  Hum Reprod. 1997;  12(2) 241-243
    CrossrefPubMedGoogle Scholar
  • 21 Broekmans F J, Kwee J, Hendriks D J, Mol B W, Lambalk C B. A systematic review of tests predicting ovarian reserve and IVF outcome.  Hum Reprod Update. 2006;  12(6) 685-718
    CrossrefPubMedGoogle Scholar
  • 22 Kalantaridou S N, Davis S R, Nelson L M. Premature ovarian failure.  Endocrinol Metab Clin North Am. 1998;  27(4) 989-1006
    CrossrefPubMedGoogle Scholar
  • 23 Alper M M, Garner P R, Seibel M M. Premature ovarian failure. Current concepts.  J Reprod Med. 1986;  31(8) 699-708
    PubMedGoogle Scholar
  • 24 Alzubaidi N H, Chapin H L, Vanderhoof V H, Calis K A, Nelson L M. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure.  Obstet Gynecol. 2002;  99(5 Pt 1) 720-725
    CrossrefPubMedGoogle Scholar
  • 25 Tibiletti M G, Testa G, Vegetti W et al. The idiopathic forms of premature menopause and early menopause show the same genetic pattern.  Hum Reprod. 1999;  14(11) 2731-2734
    CrossrefPubMedGoogle Scholar
  • 26 Rebar R W, Erickson G F, Yen S SC. Idiopathic premature ovarian failure: clinical and endocrine characteristics.  Fertil Steril. 1982;  37(1) 35-41
    PubMedGoogle Scholar
  • 27 Manuel M, Katayama P K, Jones Jr H W. The age of occurrence of gonadal tumors in intersex patients with a Y chromosome.  Am J Obstet Gynecol. 1976;  124(3) 293-300
    PubMedGoogle Scholar
  • 28 Sherman S L. Premature ovarian failure in the fragile X syndrome.  Am J Med Genet. 2000;  97(3) 189-194
    CrossrefPubMedGoogle Scholar
  • 29 Fu Y H, Kuhl D P, Pizzuti A et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox.  Cell. 1991;  67(6) 1047-1058
    CrossrefPubMedGoogle Scholar
  • 30 Oberlé I, Rousseau F, Heitz D et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome.  Science. 1991;  252 1097-1102
    CrossrefPubMedGoogle Scholar
  • 31 Verkerk A J, Pieretti M, Sutcliffe J S et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.  Cell. 1991;  65(5) 905-914
    CrossrefPubMedGoogle Scholar
  • 32 van Kasteren Y M, Hundscheid R D, Smits A P, Cremers F P, van Zonneveld P, Braat D D. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease?.  Hum Reprod. 1999;  14(10) 2455-2459
    CrossrefPubMedGoogle Scholar
  • 33 LaBarbera A R, Miller M M, Ober C, Rebar R W. Autoimmune etiology in premature ovarian failure.  Am J Reprod Immunol Microbiol. 1988;  16(3) 115-122
    PubMedGoogle Scholar
  • 34 Kim T J, Anasti J N, Flack M R, Kimzey L M, Defensor R A, Nelson L M. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure.  Obstet Gynecol. 1997;  89(5 Pt 1) 777-779
    CrossrefPubMedGoogle Scholar
  • 35 Ahonen P, Koskimies S, Lokki M L, Tiilikainen A, Perheentupa J. The expression of autoimmune polyglandular disease type I appears associated with several HLA-A antigens but not with HLA-DR.  J Clin Endocrinol Metab. 1988;  66(6) 1152-1157
    CrossrefPubMedGoogle Scholar
  • 36 Wheatcroft N, Weetman A P. Is premature ovarian failure an autoimmune disease?.  Autoimmunity. 1997;  25(3) 157-165
    CrossrefPubMedGoogle Scholar
  • 37 Betterle C, Volpato M, Rees Smith B et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease.  J Clin Endocrinol Metab. 1997;  82(3) 932-938
    CrossrefPubMedGoogle Scholar
  • 38 Keshavarz H, Hillis S D, Kieke B A, Marchbanks P A. Hysterectomy surveillance–United States—1994–1999.  Morb Mortal Wkly Rep CDC Surveillance Summ. 2002;  51 1-8
    PubMedGoogle Scholar
  • 39 Lass A. The fertility potential of women with a single ovary.  Hum Reprod Update. 1999;  5(5) 546-550
    CrossrefPubMedGoogle Scholar
  • 40 Parker W H, Broder M S, Liu Z, Shoupe D, Farquhar C, Berek J S. Ovarian conservation at the time of hysterectomy for benign disease.  Clin Obstet Gynecol. 2007;  50(2) 354-361
    CrossrefPubMedGoogle Scholar
  • 41 Rocca W A, Bower J H, Maraganore D M et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause.  Neurology. 2007;  69(11) 1074-1083
    CrossrefPubMedGoogle Scholar
  • 42 Ozdemir S, Celik C, Görkemli H, Kiyici A, Kaya B. Compared effects of surgical and natural menopause on climacteric symptoms, osteoporosis, and metabolic syndrome.  Int J Gynaecol Obstet. 2009;  106(1) 57-61
    CrossrefPubMedGoogle Scholar
  • 43 Gallagher J C. Effect of early menopause on bone mineral density and fractures.  Menopause. 2007;  14(3 Pt 2) 567-571
    CrossrefPubMedGoogle Scholar
  • 44 Jacobsen B K, Knutsen S F, Fraser G E. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study.  J Clin Epidemiol. 1999;  52(4) 303-307
    CrossrefPubMedGoogle Scholar
  • 45 de Kleijn M J, van der Schouw Y T, Verbeek A L, Peeters P H, Banga J D, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women.  Am J Epidemiol. 2002;  155(4) 339-345
    CrossrefPubMedGoogle Scholar
  • 46 Mondul A M, Rodriguez C, Jacobs E J, Calle E E. Age at natural menopause and cause-specific mortality.  Am J Epidemiol. 2005;  162(11) 1089-1097
    CrossrefPubMedGoogle Scholar
  • 47 Cummings S R, Browner W S, Bauer D Study of Osteoporotic Fractures Research Group et al. Endogenous hormones and the risk of hip and vertebral fractures among older women.  N Engl J Med. 1998;  339(11) 733-738
    CrossrefPubMedGoogle Scholar
  • 48 Pansini F, Bagni B, Bonaccorsi G et al. Oophorectomy and spine bone density: evidence of a higher rate of bone loss in surgical compared with spontaneous menopause.  Menopause. 1995;  2 109-115
    PubMedGoogle Scholar
  • 49 Aitken J M, Hart D M, Anderson J B, Lindsay R, Smith D A, Speirs C F. Osteoporosis after oophorectomy for non-malignant disease in premenopausal women.  BMJ. 1973;  2(5862) 325-328
    CrossrefPubMedGoogle Scholar
  • 50 Gambacciani M, Spinetti A, de Simone L et al. The relative contributions of menopause and aging to postmenopausal vertebral osteopenia.  J Clin Endocrinol Metab. 1993;  77(5) 1148-1151
    CrossrefPubMedGoogle Scholar
  • 51 Gärdsell P, Johnell O, Nilsson B E. The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years.  Calcif Tissue Int. 1991;  49(2) 90-94
    CrossrefPubMedGoogle Scholar
  • 52 Tuppurainen M, Kröger H, Honkanen R et al. Risks of perimenopausal fractures—a prospective population-based study.  Acta Obstet Gynecol Scand. 1995;  74(8) 624-628
    CrossrefPubMedGoogle Scholar
  • 53 van der Klift M, de Laet C E, McCloskey E V et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study.  J Bone Miner Res. 2004;  19(7) 1172-1180
    CrossrefPubMedGoogle Scholar
  • 54 Ross R. Atherosclerosis—an inflammatory disease.  N Engl J Med. 1999;  340(2) 115-126
    CrossrefPubMedGoogle Scholar
  • 55 Bush D E, Jones C E, Bass K M, Walters G K, Bruza J M, Ouyang P. Estrogen replacement reverses endothelial dysfunction in postmenopausal women.  Am J Med. 1998;  104(6) 552-558
    CrossrefPubMedGoogle Scholar
  • 56 de Kleijn M J, Wilmink H W, Bots M L et al. Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women.  Atherosclerosis. 2001;  159(2) 357-365
    CrossrefPubMedGoogle Scholar
  • 57 Virdis A, Ghiadoni L, Pinto S et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women.  Circulation. 2000;  101(19) 2258-2263
    PubMedGoogle Scholar
  • 58 Kalantaridou S N, Naka K K, Papanikolaou E et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy.  J Clin Endocrinol Metab. 2004;  89(8) 3907-3913
    CrossrefPubMedGoogle Scholar
  • 59 Dørum A, Tonstad S, Liavaag A H, Michelsen T M, Hildrum B, Dahl A A. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2).  Gynecol Oncol. 2008;  109(3) 377-383
    CrossrefPubMedGoogle Scholar
  • 60 Simoncini T, Hafezi-Moghadam A, Brazil D P, Ley K, Chin W W, Liao J K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase.  Nature. 2000;  407(6803) 538-541
    CrossrefPubMedGoogle Scholar
  • 61 Post W S, Goldschmidt-Clermont P J, Wilhide C C et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system.  Cardiovasc Res. 1999;  43(4) 985-991
    CrossrefPubMedGoogle Scholar
  • 62 Mikkola T S, Clarkson T B. Estrogen replacement therapy, atherosclerosis, and vascular function.  Cardiovasc Res. 2002;  53(3) 605-619
    CrossrefPubMedGoogle Scholar
  • 63 Phillips L S, Langer R D. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis.  Fertil Steril. 2005;  83(3) 558-566
    CrossrefPubMedGoogle Scholar
  • 64 Sack M N, Rader D J, Cannon III R O. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women.  Lancet. 1994;  343(8892) 269-270
    CrossrefPubMedGoogle Scholar
  • 65 Koh K K, Jin D K, Yang S H et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women.  Circulation. 2001;  103(15) 1961-1966
    CrossrefPubMedGoogle Scholar
  • 66 Bachmann G, Oza D. Female androgen insufficiency.  Obstet Gynecol Clin North Am. 2006;  33(4) 589-598
    CrossrefPubMedGoogle Scholar
  • 67 Sluijmer A V, Heineman M J, De Jong F H, Evers J L. Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy.  J Clin Endocrinol Metab. 1995;  80(7) 2163-2167
    CrossrefPubMedGoogle Scholar
  • 68 van der Stege J G, Groen H, van Zadelhoff S J et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure.  Menopause. 2008;  15(1) 23-31
    CrossrefPubMedGoogle Scholar
  • 69 Hartmann B W, Kirchengast S, Albrecht A, Laml T, Söregi G, Huber J C. Androgen serum levels in women with premature ovarian failure compared to fertile and menopausal controls.  Gynecol Obstet Invest. 1997;  44(2) 127-131
    CrossrefPubMedGoogle Scholar
  • 70 Elias A N, Pandian M R, Rojas F J. Serum levels of androstenedione, testosterone and dehydroepiandrosterone sulfate in patients with premature ovarian failure to age-matched menstruating controls.  Gynecol Obstet Invest. 1997;  43(1) 47-48
    CrossrefPubMedGoogle Scholar
  • 71 Davison S L, Bell R, Donath S, Montalto J G, Davis S R. Androgen levels in adult females: changes with age, menopause, and oophorectomy.  J Clin Endocrinol Metab. 2005;  90(7) 3847-3853
    CrossrefPubMedGoogle Scholar
  • 72 Løkkegaard E, Jovanovic Z, Heitmann B L, Keiding N, Ottesen B, Pedersen A T. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy.  Maturitas. 2006;  53(2) 226-233
    CrossrefPubMedGoogle Scholar
  • 73 van Der Voort D J, van Der Weijer P H, Barentsen R. Early menopause: increased fracture risk at older age.  Osteoporos Int. 2003;  14(6) 525-530
    CrossrefPubMedGoogle Scholar
  • 74 Pouillès J M, Trémollières F, Bonneu M, Ribot C. Influence of early age at menopause on vertebral bone mass.  J Bone Miner Res. 1994;  9(3) 311-315
    CrossrefPubMedGoogle Scholar
  • 75 Chetkowski R J, Meldrum D R, Steingold K A et al. Biologic effects of transdermal estradiol.  N Engl J Med. 1986;  314(25) 1615-1620
    CrossrefPubMedGoogle Scholar
  • 76 Scarabin P Y, Oger E, Plu-Bureau G. Estrogen and Thromboembolism Risk Study Group . Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.  Lancet. 2003;  362(9382) 428-432
    CrossrefPubMedGoogle Scholar
  • 77 Straczek C, Oger E, Yon de Jonage-Canonico M B Estrogen and Thromboembolism Risk (ESTHER) Study Group et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.  Circulation. 2005;  112(22) 3495-3500
    CrossrefPubMedGoogle Scholar
  • 78 Scarabin P Y, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.  Arterioscler Thromb Vasc Biol. 1997;  17(11) 3071-3078
    CrossrefPubMedGoogle Scholar
  • 79 Conard J, Samama M, Basdevant A, Guy-Grand B, de Lignières B. Differential AT III-response to oral and parenteral administration of 17 beta-estradiol.  Thromb Haemost. 1983;  49(3) 252
    PubMedGoogle Scholar
  • 80 Høibraaten E, Mowinckel M C, de Ronde H, Bertina R M, Sandset P M. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.  Br J Haematol. 2001;  115(2) 415-420
    CrossrefPubMedGoogle Scholar
  • 81 Mashchak C A, Lobo R A, Dozono-Takano R et al. Comparison of pharmacodynamic properties of various estrogen formulations.  Am J Obstet Gynecol. 1982;  144(5) 511-518
    PubMedGoogle Scholar
  • 82 Pike M C, Peters R K, Cozen W et al. Estrogen-progestin replacement therapy and endometrial cancer.  J Natl Cancer Inst. 1997;  89(15) 1110-1116
    CrossrefPubMedGoogle Scholar
  • 83 de Ziegler D, Ferriani R, Moraes L A, Bulletti C. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens.  Hum Reprod. 2000;  15(Suppl 1) 149-158
    PubMedGoogle Scholar
  • 84 Cicinelli E, de Ziegler D, Alfonso R, Nicoletti R, Bellavia M, Colafiglio G. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study.  Fertil Steril. 2005;  83(6) 1859-1863
    CrossrefPubMedGoogle Scholar
  • 85 Shifren J L. The role of androgens in female sexual dysfunction.  Mayo Clin Proc. 2004;  79(4, Suppl) S19-S24
    PubMedGoogle Scholar
  • 86 Davison S L, Davis S R. Androgens in women.  J Steroid Biochem Mol Biol. 2003;  85(2–5) 363-366
    CrossrefPubMedGoogle Scholar
  • 87 Papalia M A, Davis S R. What is the rationale for androgen therapy for women?.  Treat Endocrinol. 2003;  2(2) 77-84
    CrossrefPubMedGoogle Scholar
  • 88 Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis S R. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen.  J Clin Endocrinol Metab. 2001;  86(1) 158-161
    CrossrefPubMedGoogle Scholar
  • 89 Dimitrakakis C, Bondy C. Androgens and the breast.  Breast Cancer Res. 2009;  11(5) 212
    CrossrefPubMedGoogle Scholar
  • 90 Shifren J L, Davis S R, Dennerstein L et al. The role of testosterone therapy in postmenopausal women: position statement of the North American Menopause Society.  Menopause. 2005;  12 497-511
    CrossrefPubMedGoogle Scholar
  • 91 North American Menopause Society . The role of calcium in peri- and postmenopausal women: 2006 position statement of the North American Menopause Society.  Menopause. 2006;  13(6) 862-877 quiz 878-880
    CrossrefPubMedGoogle Scholar
  • 92 Rebar R W. Premature ovarian failure. In: Lobo RA Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Oxford, United Kingdom; Academic Press 2007: 99-109
    PubMedGoogle Scholar
  • 93 Langrish J P, Mills N L, Bath L E et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure.  Hypertension. 2009;  53(5) 805-811
    CrossrefPubMedGoogle Scholar
  • 94 Karnis M F, Zimon A E, Lalwani S I, Timmreck L S, Klipstein S, Reindollar R H. Risk of death in pregnancy achieved through oocyte donation in patients with Turner syndrome: a national survey.  Fertil Steril. 2003;  80(3) 498-501
    CrossrefPubMedGoogle Scholar
  • 95 Practice Committee, American Society for Reproductive Medicine . Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome.  Fertil Steril. 2005;  83(4) 1074-1075
    CrossrefPubMedGoogle Scholar
  • 96 Sermon K, Seneca S, De Rycke M et al. PGD in the lab for triplet repeat diseases—myotonic dystrophy, Huntington's disease and fragile-X syndrome.  Mol Cell Endocrinol. 2001;  183(Suppl 1) S77-S85
    CrossrefPubMedGoogle Scholar
  • 97 Al Kadri H, Hassan S, Al-Fozan H M, Hajeer A. Hormone therapy for endometriosis and surgical menopause.  Cochrane Database Syst Rev. 2009;  1(1) CD005997
    PubMedGoogle Scholar

Pinar H KodamanM.D. Ph.D. 

Assistant Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine

310 Cedar Street, FMB 329G, New Haven, CT 06510

Email: pinar.kodaman@yale.edu

      >